Chi-Med Announces Proposed Offering of ADSs (RNS)

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION London: Tuesday, October 24, 2017: Hutchison China MediTech

公告及新聞稿, 新聞稿, 腫瘤學 / 免疫學 | 2017-10-17

和黃醫藥聯合阿斯利康開發的沃利替尼二線治療MET擴增的EGFR突變肺癌患者展現出良好的臨床抗腫瘤活性

1 個附件

– 沃利替尼聯合泰瑞莎® 或易瑞沙® 的臨床研究數據於世界肺癌大會公佈– –新公佈的數據有助於理解MET 擴增的EGFR突變NSCLC的疾病進展過程和探索潛在的新一代治療策略–

下載新聞稿 (PDF)

公告及新聞稿, 新聞稿, 腫瘤學 / 免疫學 | 2017-10-16

和黃醫藥公佈呋喹替尼聯合療法用於肺癌一線治療的II期臨床研究初步結果

1 個附件

– 呋喹替尼聯合易瑞沙® （吉非替尼）展現出良好的療效和安全性– – 進一步證實呋喹替尼因其高選擇性和出眾的安全性而具有與其他癌症療法相聯合的巨大潛力– 2017年10

下載新聞稿 (PDF)

公告及新聞稿, 新聞稿, 集團 | 2017-10-12

和黃醫藥董事會董事任命

1 個附件

2017 年10 月12 日：和黃中國醫藥科技有限公司（簡稱“ 和黃醫藥 ”或“Chi-Med”）（納斯達克/倫敦證交所：HCM）今日宣布任命莫樹錦（Tony Mok ）教授擔任公司獨立非執行董事，同時擔任

下載新聞稿 (PDF)

公告及新聞稿, 新聞稿, 腫瘤學 / 免疫學 | 2017-09-29

Chi-Med Highlights Oral Presentations at CSCO Annual Meeting

Press Release – Three oral presentations given at CSCO for fruquintinib, savolitinib and theliatinib – – Plenary keynote presentation for FRESCO Phase III trial details analysis showing consistent survival benefit in all key subgroups

公告及新聞稿, 新聞稿, 腫瘤學 / 免疫學 | 2017-09-29

Chi-Med to Present Savolitinib and Fruquintinib Clinical Data at WCLC 2017 Annual Meeting

Press Release – Data to show potential of savolitinib to treat EGFR-TKI resistance in both Iressa® and Tagrisso® refractory patients with MET amplification – – Results to further validate Chi-Med’s scientific strategy of designing highly

公告及新聞稿, 新聞稿, 腫瘤學 / 免疫學 | 2017-08-29

和黃醫藥在中國啟動高選擇性PI3Kδ抑製劑HMPL-689以淋巴瘤為適應症的I期臨床試驗

1 個附件

2017年8月29日：和黃醫藥今日宣佈在中國啟動HMPL-689的I期臨床試驗。HMPL-689是一種新型高選擇性強效小分子抑製劑，靶向B 細胞受體信號通路中的關鍵蛋白磷酸肌醇-3激酶δ異構體（PI3Kδ）。 �

下載新聞稿 (PDF)

公告及新聞稿, 集團 | 2017-07-31

Chi-Med Reports 2017 Interim Results and Updates Shareholders on Key Clinical Programs

London: Monday, July 31, 2017: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM), the China-based biopharmaceutical company focused on discovering and developing targeted therapies for oncology and immunological diseases for the glob

公告及新聞稿, 新聞稿, 腫瘤學 / 免疫學 | 2017-06-29

和黃醫藥與阿斯利康聯手啟動沃利替尼治療乳頭狀腎細胞癌的全球III期臨床試驗“SAVOIR”

1 個附件

阿斯利康製藥（“阿斯利康”） (LON/STO/NYSE: AZN) 和黃中國醫藥科技有限公司（簡稱 “和黃醫藥”）（納斯達克/倫敦證交所：HCM） 2017 年6 月29 日：和黃醫藥今日宣布

下載新聞稿 (PDF)

公告及新聞稿, 新聞稿, 集團 | 2017-06-29

Chi-Med to Announce 2017 Half-Year Financial Results

London: Thursday, June 29, 2017: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) will be announcing its interim results for the six months ended June 30, 2017 on Monday, July 31, 2017 at 7:00 am British Summer Time (BST). An ana

公告及新聞稿, 新聞稿, 腫瘤學 / 免疫學 | 2017-06-22

和黃醫藥在中國啟動新型FGFR抑製劑HMPL 453的I/II期臨床試驗

1 個附件

2017年6月22日：和黃醫藥近日在中國啟動HMPL-453的I/II期臨床試驗。HMPL-453是一種靶向成纖維細胞生長因子受體（FGFR）的新型高選擇性小分子抑製劑。2017年6月19日首位受試者接受給藥治療。該�

下載新聞稿 (PDF)

公告及新聞稿, 新聞稿, 腫瘤學 / 免疫學 | 2017-06-12

和黃醫藥向國家食品藥品監督管理局遞交呋喹替尼治療晚期結直腸癌的新藥上市申請

1 個附件

– 國家食品藥品監督管理局已受理申請，並將由藥品審評中心作技術審核– –將收到來自禮來共計3080萬人民幣的里程碑付款– 2017年6月12日：和黃醫藥今日宣布藥物呋喹替�

下載新聞稿 (PDF)

公告及新聞稿, 新聞稿, 腫瘤學 / 免疫學 | 2017-06-05

和黃醫藥在ASCO年會上就呋喹替尼臨床III期研究數據進行口頭報告

1 個附件

2017年6月5日：和黃醫藥宣佈在今天於美國芝加哥舉行的美國臨床腫瘤學會（ASCO）年會上就其自主研發的高選擇性血管細胞內皮生長因子受體（VEGFR）抑製劑的關鍵III期臨床研究結果進行了口�

下載新聞稿 (PDF)

公告及新聞稿, 新聞稿, 腫瘤學 / 免疫學 | 2017-05-18

和黃醫藥在ASCO 2017年會上公佈臨床數據

1 個附件

–受ASCO組委會邀請口頭報告呋喹替尼治療結直腸癌的III 期臨床研究“ FRESCO”的研究結果– –將在大會上展示呋喹替尼，沃利替尼和索凡替尼共5項研究摘要– 2017年5

下載新聞稿 (PDF)

公告及新聞稿, 新聞稿, 腫瘤學 / 免疫學 | 2017-04-07

和黃醫藥在2017年AACR年會上公佈呋喹替尼和索凡替尼的臨床前數據

1 個附件

2017 年4 月7 日：和黃醫藥在2017 年4 月1 日至5 日於美國華盛頓舉行的美國癌症研究協會(AACR) 年會上公佈了呋喹替尼和索凡替尼的臨床前數據。呋喹替尼和索凡替尼目前都在以多種癌症�

下載新聞稿 (PDF)

公告及新聞稿, 集團 | 2017-03-27

2016 Annual Report and Notice of Annual General Meeting

London: Monday, March 27, 2017: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that its 2016 Annual Report together with the Notice of Annual General Meeting and the Form of Proxy have been posted to shareholders.

公告及新聞稿, 新聞稿, 集團 | 2017-03-24

Chi-Med Appoints Weiguo Su, Chief Scientific Officer, to Board of Directors

Appointment of Director London: Friday, March 24, 2017: Hutchison China MediTech Limited (“Chi-Med” or the “Company”) (AIM/Nasdaq: HCM) today announces that Dr Weiguo Su has been appointed as Executive Director and member of Technical Commi

公告及新聞稿, 新聞稿, 腫瘤學 / 免疫學 | 2017-03-21

Chi-Med to host R&D Briefings on March 29 & 30, 2017

Press Release London: Tuesday, March 21, 2017: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that it will host Research & Development (“R&D”) briefings in London and New York to provide an overview o

公告及新聞稿, 新聞稿, 集團 | 2017-03-16

Grant of Awards under Long Term Incentive Plan

Press Release London: Thursday, March 16, 2017: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) announces that on March 15, 2017, it granted conditional awards (“LTIP Awards”) under the Long Term Incentive Plan (“LTIP”) a

公告及新聞稿, 集團 | 2017-03-13

Publication of Form 20-F for the Year Ended December 31, 2016

London: Monday, March 13, 2017: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today published the Form 20-F for the financial year ended December 31, 2016 per attached and also available for viewing on the Company's website at ww

公告及新聞稿, 集團 | 2017-03-13

Chi-Med Reports Final Results for the Year Ended December 31, 2016 and Updates on Key Clinical Programs

Hutchison China MediTech Limited (“Chi-Med”) Reports Final Results for the Year Ended December 31, 2016 and Updates Shareholders on Key Clinical Programs Group: Record revenue, net income and clinical investment in 2016 Group revenue up 21%

公告及新聞稿, 新聞稿, 腫瘤學 / 免疫學 | 2017-03-10

和黃醫藥在歐洲神經內分泌腫瘤學會年會上公佈索凡替尼治療神經內分泌瘤Ib /II期臨床試驗結果

1 個附件

2017 年3 月10 日：和黃醫藥在2017 年3 月8 日至10 日於西班牙巴塞羅那舉行的第14 屆歐洲神經內分泌腫瘤學會年會（ENETS）上公佈了索凡替尼正在進行的治療晚期神經內分泌瘤的Ib /II 期�

下載新聞稿 (PDF)

公告及新聞稿, 腫瘤學 / 免疫學 | 2017-03-03

和黃醫藥宣布呋喹替尼（HMPL-013）以局部晚期或轉移性結直腸癌為適應症的III期臨床試驗“FRESCO”取得成功

1 個附件

– 達到首要和次要終點– –安全性及療效達到預期– – 計劃於2017年中遞交中國新藥上市申請– –完整詳細的試驗結果將在2017年中通過腫瘤學術大會公佈– 2017年3月3日：和黃醫�

查看公告 (PDF)

公告及新聞稿, 新聞稿, 集團 | 2017-02-28

Chi-Med Appoints Graeme Jack as Independent Non-executive Director and Chairman of Audit Committee

Change of Directors London: Tuesday, February 28, 2017: Hutchison China MediTech Limited (“Chi-Med” or the “Company”) (AIM/Nasdaq: HCM) today announces that with effect from March 1, 2017:- Mr Graeme Allan Jack has been appointed as I

公告及新聞稿, 新聞稿, 腫瘤學 / 免疫學 | 2017-02-20

Chi-Med Initiates a Phase II Study of Savolitinib in Pulmonary Sarcomatoid Carcinoma

Press Release London: Monday, February 20, 2017: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that a Phase II study of savolitinib has been initiated in locally advanced or metastatic pulmonary sarcomatoid carci

公告及新聞稿, 新聞稿, 腫瘤學 / 免疫學 | 2017-02-14

Chi-Med Initiates First-In-Human Clinical Trial of Novel FGFR Inhibitor HMPL-453 in Australia

London: Tuesday, February 14, 2017: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that it has initiated the first-in-human (“FIH”) Phase I clinical trial of HMPL-453 in Australia. HMPL-453 is a novel, highly

公告及新聞稿, 新聞稿, 腫瘤學 / 免疫學 | 2017-02-14

Chi-Med and AstraZeneca Present Savolitinib Papillary Renal Cell Carcinoma Phase II Results at 2017 Genitourinary Cancers Symposium

Press Release London: Tuesday, February 14, 2017: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) and AstraZeneca PLC (“AstraZeneca”) will present data from the ongoing Phase II clinical trial of savolitinib in patients wi

公告及新聞稿, 新聞稿, 集團 | 2017-02-01

Chi-Med Appoints Industry Veteran Karen Ferrante to Board of Directors

Change of Directors London: Wednesday, February 1, 2017: Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) today announces that with effect from today:- Dr Karen Jean Ferrante has been appointed as Independent Non-Executive Director

公告及新聞稿, 新聞稿, 集團 | 2017-01-16

Chi-Med Appoints Industry Veteran Paul Carter to Board of Directors

Change of Directors London: Monday, January 16, 2017: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces with effect from February 1, 2017, Mr Paul Rutherford Carter has been appointed as Senior Independent Non-Execut

公告及新聞稿, 新聞稿, 腫瘤學 / 免疫學 | 2017-01-16

Chi-Med Initiates a Phase II Combination Study of Fruquintinib with Iressa® (gefitinib) in First-Line Non-Small Cell Lung Cancer

London: Monday, January 16, 2017: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq:HCM) today announces that it has initiated a Phase II study of a combination therapy using fruquintinib and Iressa® in the first-line setting for patients

公告及新聞稿, 新聞稿, 腫瘤學 / 免疫學 | 2017-01-16

Chi-Med Initiates a Phase II Study of Sulfatinib in Second-line Biliary Tract Cancer in China

London: Monday, January 16, 2017: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that it has initiated a Phase II study of sulfatinib in second-line biliary tract cancer (“BTC”) patients in China. Sulfatinib

公告及新聞稿, 新聞稿, 腫瘤學 / 免疫學 | 2017-01-16

Chi-Med Presents Phase I/II Clinical Data for Selective VEGFR Inhibitor Fruquintinib at the 2017 Gastrointestinal Cancers Symposium

London: Monday, January 16, 2017: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that data from the ongoing Phase I/II clinical trial of fruquintinib in combination with paclitaxel (Taxol®) in second-line patients

公告及新聞稿, 新聞稿, 腫瘤學 / 免疫學 | 2017-01-10

Chi-Med Initiates HMPL-523 Clinical Trials in Hematological Cancer in China

London: Tuesday, January 10, 2017: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that it has initiated a Phase I trial of its novel spleen tyrosine kinase (“Syk”) inhibitor, HMPL-523, in patients with hematolo

公告及新聞稿, 新聞稿, 腫瘤學 / 免疫學 | 2016-12-06

Chi-Med Presents Pre-clinical Data for Selective Syk Inhibitor HMPL-523 at the 2016 American Society of Hematology Annual Meeting

Press Release London: Tuesday, December 6, 2016: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that data from a recent pre-clinical study, investigating the in vitro and in vivo anti-tumor activities of novel Spl

公告及新聞稿, 新聞稿, 腫瘤學 / 免疫學 | 2016-11-23

Chi-Med to Present Data from Proof-of-Concept Clinical Trials for Fruquintinib and Epitinib at the 17th World Conference on Lung Cancer (“WCLC”)

Press Release London: Wednesday, November 23, 2016: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that results from two non-small cell lung cancer (“NSCLC”) clinical studies will be presented at WCLC in Vienn

公告及新聞稿, 新聞稿, 腫瘤學 / 免疫學 | 2016-11-14

Chi-Med Presents Phase I Clinical Data for Selective Syk Inhibitor HMPL-523 at the 2016 ACR/ARHP Annual Meeting

Press Release London: Monday, November 14, 2016: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that data from a recent Phase I, first-in-human, dose escalating study of the safety, tolerability and pharmacokineti

公告及新聞稿, 其他業務, 新聞稿 | 2016-10-31

Chi-Med Commercial Platform Joint Venture Receives US$59.5 Million Land Compensation Payment

Shanghai agreement triggers a one-time gain to Chi-Med of US$38.2 million in Q4 2016 Shanghai factory relocation complete: now operational with three-fold increase in capacity Cash from Chi-Med Commercial Platform supports developmen

公告及新聞稿, 集團 | 2016-08-02

Change of Non-executive Directors

London: Tuesday, August 2, 2016: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces with effect from August 1, 2016, Dr Dan Eldar has been appointed as a Non-Executive Director of Chi-Med in place of Mr Salbaing who ha

公告及新聞稿, 集團 | 2016-08-02

Chi-Med Reports Interim Results for the Six Months Ended June 30, 2016, Provides 2016 Financial Guidance and Updates Shareholders on Key Clinical Programs

Group revenue up 27% to $104.5 million (H1 2015: $82.5m) and net income attributable to Chi‑Med of $0.5 million (H1 2015: $15.9m), reflecting a sharp increase in clinical investment. Innovation Platform – Seven drug candidates in 25

公告及新聞稿, 腫瘤學 / 免疫學 | 2016-08-01

為加快沃利替尼全球研發項目，和黃醫藥與阿斯利康簽署共同開發補充協議

1 個附件

首個以c-Met 異常乳頭狀腎細胞癌（“PRCC”）為適應症的全球III 期臨床試驗將於近期啟動 2016年8月1日：和黃醫藥和阿斯利康今日宣佈在2011年雙方就沃利替尼達成的合作協議的基礎�

查看公告 (PDF)

公告及新聞稿, 集團 | 2016-07-05

Chi-Med to Announce 2016 Half-Year Financial Results

London: Tuesday, July 5, 2016: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) will be announcing its interim results for the six months ended June 30, 2016 on Tuesday, August 2, 2016 at 7:00 am British Summer Time (BST). An a

公告及新聞稿, 腫瘤學 / 免疫學 | 2016-06-20

和黃醫藥啟動沃利替尼以EGFR突變非小細胞肺癌為適應症的全球II期臨床試驗

1 個附件

擴展的非小細胞肺癌II期臨床試驗啟動，阿斯利康向和黃醫藥支付1000萬美元里程金此研究的開展是基於沃利替尼早先與Tagrisso 或Iressa 聯合用藥治療c-Met擴增非小細胞肺癌的初始小型I

查看公告 (PDF)

公告及新聞稿, 腫瘤學 / 免疫學 | 2016-05-13

和黃醫藥完成呋喹替尼以結直腸癌為適應症的III期臨床試驗的患者入組工作，共招募416名患者

1 個附件

2016年5月13日：和黃醫藥今日宣布呋喹替尼（HMPL-013）以結直腸癌為適應症的III 期臨床試驗“ FRESCO” 順利完成患者入組工作。2012年，中國新發結直腸癌病例約為39萬例，呋喹替尼的這項關�

查看公告 (PDF)

公告及新聞稿, 集團 | 2016-04-13

Hutchison China MediTech Limited Announces Exercise of Overallotment Option

London: Wednesday, April 13, 2016: Hutchison China MediTech Limited ("Chi-Med") (Nasdaq/AIM: HCM) announces that the underwriters of its offering of American depositary shares (“ADSs”) on the Nasdaq Global Select Market (the “Offering”) have

公告及新聞稿, 腫瘤學 / 免疫學 | 2016-04-12

Chi-Med initiates first-in-human clinical trial of novel PI3K inhibitor HMPL-689

London: Tuesday, April 12, 2016: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that Hutchison MediPharma Limited (“HMP”), its drug R&D subsidiary, has initiated the first-in-human (“FIH”) Phase I cli

公告及新聞稿, 新聞稿, 集團 | 2016-03-22

Closing of U.S. Public Offering of ADSs Raising Approximately US$101 Million on the Nasdaq Stock Market

NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION OR DISSEMINATION IN OR INTO OR FROM THE UNITED STATES, CANADA, AUSTRALIA, JAPAN OR SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD CONSTIT

公告及新聞稿, 腫瘤學 / 免疫學 | 2016-03-21

Chi-Med initiates sulfatinib Phase III registration study in pancreatic neuroendocrine tumor patients

London: Monday, March 21, 2016: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that Hutchison MediPharma Limited (“HMP”), its drug R&D subsidiary, has initiated SANET-p, a Phase III registration trial of s

公告及新聞稿, 集團 | 2016-03-18

Final Prospectus

公告及新聞稿, 集團 | 2016-03-17

Pricing of U.S. Public Offering of ADSs

公告及新聞稿, 新聞報導, 集團 | 2016-03-17

Hutchison China MediTech Limited Announces Pricing of U.S. Public Offering of ADSs

Press Release London: Wednesday, March 16, 2016: Hutchison China MediTech Limited ("Chi Med") (AIM: HCM) announces the pricing of its U.S. public offering of American depositary shares (“ADSs”) (the “Offering”), raising gross proceeds of app

1 2 3 4 5

7 8 9